logo

For the Inventor, By the Inventor

Tokyo, Japan

Aska Pharmaceutical Co., Ltd.

USPTO Granted Patents = 35

% Expired Patents = 28.6



Forward Citations = 60

Loading Chart...
Loading Chart...

69 inventors (with patents filed for the assignee):

goldMedal Makoto Okada (9 out of 37 patents)

silverMedal Youichi Nakano (7 out of 7 patents)

bronzeMedal Hiroyuki Hayashi (6 out of 53 patents)

4.  Shuichiro Sato (6 out of 11 patents)

5.  Atsushi Shinbo (6 out of 6 patents)

6.  Akira Asagarasu (6 out of 9 patents)

7.  Hideo Kobayashi (6 out of 59 patents)

8.  Koichi Miyazaki (5 out of 26 patents)

9.  Hashime Kanazawa (5 out of 7 patents)

10.  Kotaro Gotanda (5 out of 9 patents)

11.  Takayoshi Nakagawa (5 out of 6 patents)

12.  Shigeki Iwashita (4 out of 9 patents)

13.  Takahisa Saito (4 out of 8 patents)

14.  Takashi Nose (3 out of 154 patents)

15.  Kenji Shimizu (3 out of 72 patents)


Core Competencies:
Urination Disorder
Nasal Administration
Mesenchymal Stem Cell
PDE9 Inhibitors
Thienopyrimidine Derivatives
Heterocyclic Compounds
Pharmaceutical Composition
Analgesic Agent
Functional Gastrointestinal Disorder
Quinazoline Derivatives
Microneedle Device
Powder Preparation

35 patents:

1. 12458650 - Urination disorder-improving agent (2025-11-04),
2. 11752102 - Powder preparation for nasal administration (2023-09-12),
3. 11234928 - Powder preparation for nasal administration (2022-02-01),
4. 10815268 - 15-oxosteroid compound and process for producing the same (2020-10-27),
5. 10710967 - Pyrimidine derivative (2020-07-14),
6. 10640749 - Mesenchymal stem cell and the method of use thereof (2020-05-05),
7. 10632065 - Microneedle device containing recombinant follicle stimulating hormone (2020-04-28),
8. 10508130 - Crystalline polymorph of 15B-hydroxy-osaterone acetate (2019-12-17),
9. 9643994 - Crystalline polymorphic form of ulipristal acetate (2017-05-09),
10. 9643993 - Crystalline polymorphic form of ulipristal acetate (2017-05-09),
11. 9365553 - Heterocyclic compound and H1 receptor antagonist (2016-06-14),
12. 9200008 - [object Object] (2015-12-01),
13. 9115344 - Mesenchymal stem cell and a method of use thereof (2015-08-25),
14. 9040536 - Substituted pyrrolo[1,2-a]quinoxalines as PDE9 inhibitors (2015-05-26),
15. 9006253 - Crystal of 2-(3,4-dichlorobenzyl)-5-methyl-4-oxo-3,4-dihydrothieno[2,3-D]pyrimidine-6-carboxylic acid (2015-04-14),
Company Overview
Aska Pharmaceutical Co., Ltd. is a Tokyo-based company specializing in the development and manufacturing of pharmaceutical products. The organization focuses on innovative therapies across various therapeutic areas, including oncology, cardiovascular health, and infectious diseases. With a commitment to advancing healthcare, Aska engages in extensive research and development to create effective and safe medications, contributing to improved patient outcomes both in Japan and globally.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

35 Patents

#994 in Tokyo

#2,131 in Japan

#19,181 in the World

Tokyo, JP
Tokyo, Japan

Aska Pharmaceutical Co., Ltd.

Forward Citations = 60

69 inventors:

goldMedal Makoto Okada (9 out of 37 patents)

silverMedal Youichi Nakano (7 out of 7 patents)

bronzeMedal Hiroyuki Hayashi (6 out of 53 patents)

4.  Shuichiro Sato (6 out of 11 patents)

5.  Atsushi Shinbo (6 out of 6 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Aska Pharmaceutical Co., Ltd.. Retrieved from https://idiyas.com/company/aska-pharmaceutical-company

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…